Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 0.0-74.0,  Acute Myeloid Leukemia Diagnosis of primary refractory or relapsed Acute Myeloid Leukemia (AML) AND suitable for consideration of allogeneic Hematopoietic Stem Cell Transplant with confirmation of an identified eligible donor by a FACT accredited transplant center and with confirmation that the center plans to proceed with transplant if CLL-1.CAR treatment induces response they consider adequate to proceed to allogeneic HSCT 2. CLL-1 positive tumor with at least 30% CLL-1 blasts by flow cytometry or immunohistochemistry (tissue) assessed by a CLIA certified Flow Cytometry/Pathology laboratory 3. Age ≤75 years NOTE: The first six (6) patients treated on the study will be adults (≥18 yrs of age). 4. Hgb ≥ 7.0 g/dL(can be transfused) 5. Life expectancy greater than 12 wks 6. If apheresis required to collect blood PT and APTT <1.5x ULN Serum Creatinine < 1.5 x ULN AST < 1.5 x ULN 7. Informed consent  Active infection (bacterial, fungal or viral) requiring ongoing treatment without improvement. 2. Active infection with HIV or HTLV 3. Active second cancer (except non-melanoma skin cancer or in situ breast cancer or cervix cancer)or other cancer treated ≤ 2 years prior to enrollment 4. Ongoing treatment with immune suppression for prophylaxis or treatment of GVHD including high dose steroids (eg prednisone > 0.25mg/kg) - 1. Diagnosis of primary refractory or relapsed Acute Myeloid Leukemia (AML). Patients with targetable mutations should have failed or be ineligible for targeted therapies (e.g. FLT3 inhibitors, IDH inhibitors, or anti-CD33 drug conjugate). AND patients should be suitable for consideration of allogeneic Hematopoietic Stem Cell Transplant with confirmation of an identified eligible donor by a FACT accredited transplant center and with confirmation that the center plans to proceed with transplant if CLL-1.CAR treatment induces a response they consider adequate to proceed to allogeneic HSCT. 2. CLL-1 positive tumor with at least 30% CLL-1 blasts by flow cytometry or immunohistochemistry (tissue) assessed by a CLIA certified Flow Cytometry/Pathology laboratory 3. Age ≤75 years NOTE: The first six (6) patients treated on the study will be adults (≥18 yrs of age). 4. AST/ALT less than 5 times the upper limit of normal 5. Bilirubin less than 3 times the upper limit of normal 6. Estimated GFR ≥ 60ml/min 7. Pulse oximetry of > 92% on room air 8. Karnofsky/Lansky ≥ 60 9. Recovered from all acute toxic effects of prior chemotherapy at least one week before study entry and off systemic chemotherapy at least 2 weeks prior to study entry 10. Available autologous transduced activated peripheral blood T-cell product with ≥ 20% expression of CLL-1.CAR.28z by flow cytometry 11. Life expectancy > 12 weeks 12. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom 13. Informed consent explained to, understood by, and signed by patient/guardian. Patient/guardian given copy of informed consent Currently receiving any investigational agents or having received any tumor vaccines within the previous 6 weeks. 2. History of hypersensitivity reactions to murine protein-containing products. 3. Pregnant or lactating. 4. Active infection with HIV or HTLV. 5. Clinically significant bacterial, viral or fungal infection requiring ongoing antifungal therapy without improvement,. 6. Cardiac Prolonged QTc with maximum interval as defined by age with ; Uncontrolled atrial fibrillation/flutter; Myocardial infarction within the last 6 months; Cardiac echocardiography with LVSF<30% or LVEF<50% or clinically significant pericardial effusion; Cardiac dysfunction NYHA III or IV; CNS abnormalities: Presence of CNS disease defined as detectable cerebrospinal blast cells in a sample of CSF with ≥ 5 WBCs per mm3 or chloroma on imaging, History or presence of an underlying CNS disorder such as a seizure disorder requiring current use of antiepileptic medications, cerebrovascular ischemia/hemorrhage within prior 6 months, dementia, cerebellar disease, or any autoimmune disease with CNS involvement. 7. Use of serotherapy with Campath or Anti-Thymocyte Globulin (ATG) within the last 28 days 8. Use of Donor Lymphocyte Infusion (DLI) or other cellular therapy product within 30 days 9. Acute GVHD ≥ Grade 2 or moderate to severe (formerly extensive) chronic GVHD 10. Aministration of high dose steroids >1 mg/kg within the preceding 5 days or currently receiving > 0.25 mg/kg of Prednisone equivalent 11. Hyperleukocytosis (WBC ≥50K) or rapidly progressive disease that in the estimation of the investigator would compromise the ability of the patient to complete the study